Posts

Latham advises NVIDIA on US$40 Billion acquisition of Arm

Latham & Watkins LLP represents NVIDIA in its acquisition of Arm Limited (Arm) from SoftBank in a cash and stock deal valued at up to US$40 billion. The combination brings together NVIDIA’s leading AI computing platform with Arm’s vast ecosystem to create the premier computing company for the age of artificial intelligence, accelerating innovation while expanding into large, high-growth markets. SoftBank will remain committed to Arm’s long-term success through its ownership stake in NVIDIA, expected to be under 10 percent.

The Latham deal team is led by M&A partners Josh Dubofsky and Charles Ruck in Silicon Valley and New York and Ed Barnett and Farah O’Brien in London, with associates Saad Khanani, Amro Suboh, Hector Sants, Stephanie Isaia, Oliver Cohen, Rachelle Polsky, Michael O’Halloran, Andria Varnavides, Angharad Simon, and Saavan Shah. San Francisco partner Joshua Holian, Brussels partner Sven Völcker, Washington, D.C. partner Les Carnegie, and London partners David Little and Charles Claypoole advised on regulatory matters with counsels Rita Motta, Jana Dammann, and Annie Froehlich, and associates Sophia Bertran, Natasha Pardawala, Giuditta Caldini, Alexandra Luchian, Niklas Brüggemann, and Rob Price.

Advice was also provided on tax matters by Washington, D.C. partner Nicholas DeNovio and London partner Sean Finn, with associates Pierce Pandolph, Aoife McCabe, and Jared Grimley; on intellectual property matters by London partner Deborah Kirk and Silicon Valley partner Anthony Klein, with associates Arielle Singh, Kirsty Watkins, Grace Erskine, and Elva Cullen; and on benefits and employment matters by London partner Catherine Drinnan, Paris partner Matthias Rubner, Munich partner Tobias Leder, and San Francisco partner Julie Crisp, with associates James Robinson, Adam Ray, Romain Nairi, and Agathe Flandre; on real estate matters by London partner Quentin Gwyer with associate Danni Davies; and on environmental matters by London partner Paul Davies with counsel Michael Green. Additional advice on the transaction was provided by counsels Rachel Alpert and Daniel Smith, and associates Jason Despain, Yasmina Vaziri, and Marcus Tomlison.

Latham & Watkins advises Inari Medical in upsized IPO

Inari Medical, Inc., a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, has announced the pricing of its upsized initial public offering of 8,202,565 shares of its common stock at a public offering price of US$19.00 per share, for total gross proceeds of approximately US$156 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares are being offered and sold by Inari. In addition, Inari has granted the underwriters a 30-day option to purchase up to an additional 1,230,384 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Inari’s common stock began trading on the Nasdaq Global Select Market on May 22, 2020 under the symbol “NARI.”

Latham & Watkins LLP represents Inari Medical, Inc. in the initial public offering with a capital markets team led by Orange County partner Shayne Kennedy and New York partner Nathan Ajiashvili, with Orange County associates Ross McAloon, Eric Hanzich, and Jacob Walsh. Advice was also provided on benefits and compensation matters by Los Angeles partner Michelle Carpenter, with Orange County associates Sara Schlau and Gabrielle Masse; on tax matters by Los Angeles partner Samuel Weiner, with Orange County associate Janet Hsu; on intellectual property matters by Bay Area partner Judith Hasko, with San Diego associate Robert Yeh; and on regulatory matters by Washington, D.C. partner Elizabeth Richards and Brussels partner Hector Armengod, with Bay Area counsel Betty Pang, Washington, D.C. counsel Nicole Liffrig Molife, Washington, D.C. associate Chad Jennings and New York associate Heath Ingram.